Approved Research
Identification of risk factors and construction of early-diagnosis model for predicting the risk of pancreatic cancer in new-onset diabetes population based on UK Biobank data
Approved Research ID: 85224
Approval date: March 24th 2022
Lay summary
Aims: This research aimed to identify non-genetic (environmental, demographic, etc.) and genetic factors which correlated with the risk of pancreatic ductal adenocarcinoma (PDAC) in the population of new-onset diabetes (NODM) and then subsequently to build a prediction model in order to help identify subjects with a high likelihood of having PDAC-associated diabetes in the whole population present with NODM.
Scientific rationale: PDAC is associated with a very poor prognosis with a 5-year survival rate of less than 10%, principally because PDAC frequently presents at an advanced stage (85% unresectable). A screening strategy for sporadic PDAC still has not been established; given that its cancer specific symptoms occur late, early detection thereby will require screening of asymptomatic individuals. About up to 50%-80% of PDAC patients may have impaired fasting blood glucose or impaired glucose tolerance. It has been well-known that long-term diabetes increases the risk of PDAC by 40% to 100%, while the risk of PDAC in diabetic patients with a course of ! 2years -3 years (new-onset diabetes, NODM) can tremendously increase by 2 times to 7 times; moreover, about 1% patients with NODM could develop PDAC within 2 years -3 years, and it is currently believed that a large proportion of NODM are pancreatogenous diabetes mellitus caused by PDAC. Therefore, the characteristics, both genetic and non-genetic, would be different between PDAC-associated NODM and real new-onset T2DM. Through identifying the differences between PDAC patients with NODM, type 2 NODM, and healthy people, and exploring unique risk factors associated with development of PDAC in NODM population, together with advanced algorithms, may help to establish a prediction model which can help distinguish PDAC-related NODM from new-onset common T2DM patients.
Project duration: With 24 months
Public health impact: Our results may help to build a strategy for the further enrichment of high-risk cases in NODM population for cost-effective follow-up and/or detailed examination for the early diagnosis of PDAC.